INmune Bio, Inc. (INMB) Misses Q2 EPS by 65c

INmune Bio, Inc. (NASDAQ: INMB) reported Q2 EPS of ($1.05), $0.65 worse than the analyst estimate of ($0.40).

For earnings history and earnings-related data on INmune Bio, Inc. (INMB) click here.

You May Also Be Interested In

• KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
• Wolfe Research Downgrades Home Depot (HD) to Peerperform
• Taysha Gene Therapies (TSHA) PT Raised to $11 at Citizens on REVEAL Data Update